List of Excipients in Branded Drug ACETAMINOPHEN AND CODEINE

« Back to Dashboard

Generic Drugs Containing ACETAMINOPHEN AND CODEINE

Company	Ingredient	NDC	Excipient
Liberty Pharmaceuticals Inc	acetaminophen and codeine phosphate	0440-7026	CELLULOSE, MICROCRYSTALLINE
Liberty Pharmaceuticals Inc	acetaminophen and codeine phosphate	0440-7026	MAGNESIUM STEARATE
Liberty Pharmaceuticals Inc	acetaminophen and codeine phosphate	0440-7026	POVIDONES
Liberty Pharmaceuticals Inc	acetaminophen and codeine phosphate	0440-7026	SODIUM METABISULFITE
Liberty Pharmaceuticals Inc	acetaminophen and codeine phosphate	0440-7026	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in ACETAMINOPHEN AND CODEINE?

# Of NDCs	Excipient
32	CELLULOSE, MICROCRYSTALLINE
16	CROSCARMELLOSE SODIUM
16	CROSPOVIDONE
13	LACTOSE MONOHYDRATE
32	MAGNESIUM STEARATE

Acetaminophen and Codeine Excipient Strategy and Commercial Opportunities

Last updated: November 5, 2026

Acetaminophen and codeine is a mature combination with limited conventional patent value and substantial formulation, safety, and regulatory constraints. Commercial opportunity is strongest in differentiated oral dosage forms, dose-flexible products, supply-chain reliability, and excipient systems that improve stability, swallowability, taste, and manufacturing efficiency. The principal barriers are opioid controls, acetaminophen hepatotoxicity, pediatric restrictions, and the limited ability to claim abuse deterrence through excipients alone.

What is the commercial profile of acetaminophen and codeine?

Acetaminophen and codeine combines a non-opioid analgesic with an opioid agonist. U.S. products include immediate-release tablets, capsules, and oral solutions. Common tablet strengths contain 300 mg acetaminophen with 15 mg, 30 mg, or 60 mg codeine. Oral solutions vary by concentration and require tight dose-uniformity controls.

The market is mature and largely generic. Original branded products do not provide a durable exclusivity platform. Value is concentrated in:

• Reliable supply of a Schedule II or Schedule III codeine product, depending on strength and formulation.
• Lower-cost, high-throughput generic manufacturing.
• Improved liquid taste and dosing accuracy.
• Smaller tablets or capsules for patients with swallowing difficulty.
• Stable, low-moisture formulations.
• Institutional and government procurement.
• Contract manufacturing and private-label supply.

The codeine component creates controlled-substance obligations, while acetaminophen creates a separate dose-toxicity risk. FDA has required limits on acetaminophen content in prescription combination products and has emphasized the risk of accidental overdose from multiple acetaminophen-containing medicines.[1]

Which dosage forms offer the best excipient opportunities?

Immediate-release tablets and oral solutions provide the clearest formulation opportunities. Extended-release development is less attractive because it introduces additional opioid exposure, dose-dumping, abuse, and regulatory concerns without a clear market need.

Dosage form	Primary excipient objectives	Commercial opportunity	Main risk
Immediate-release tablet	Compression, disintegration, stability, low weight	Generic substitution and manufacturing efficiency	Dose uniformity and opioid controls
Film-coated tablet	Taste masking, color differentiation, swallowability	Hospital and retail differentiation	Coating cost and dissolution impact
Hard capsule	Fill uniformity, reduced tablet size	Patient-friendly products and private label	Codeine segregation during filling
Oral solution	Solubility, preservation, taste masking, dosing accuracy	Pediatric, geriatric, and institutional use where permitted	Medication errors, microbial control, opioid misuse
Unit-dose liquid	Portability and dosing control	Hospitals, long-term care, and emergency settings	Packaging and controlled-substance reconciliation
Orally disintegrating tablet	Rapid disintegration and low water requirement	Niche adherence market	Taste, dose loading, and opioid abuse concerns
Modified-release product	Release control	Limited specialty opportunity	Regulatory, safety, and abuse-deterrence burden

How should tablet excipients be selected?

A conventional immediate-release tablet can use a direct-compression or wet-granulation platform. Suitable excipient classes include:

• Fillers such as microcrystalline cellulose, lactose, mannitol, or dibasic calcium phosphate.
• Binders such as povidone, copovidone, pregelatinized starch, or hydroxypropyl cellulose.
• Disintegrants such as crospovidone, croscarmellose sodium, or sodium starch glycolate.
• Lubricants such as magnesium stearate, sodium stearyl fumarate, or stearic acid.
• Glidants such as colloidal silicon dioxide.
• Film-coating polymers such as hypromellose, polyvinyl alcohol, or methacrylate-based systems.

The most commercially practical platform is a low-weight, robust direct-compression tablet with rapid disintegration and low friability. A formulation that minimizes granulation steps can reduce energy use, solvent handling, cleaning time, and batch-cycle duration.

The key technical issue is content uniformity. Codeine is present at a much lower mass than acetaminophen in most products. Poor powder-flow or segregation behavior can produce codeine assay variability even when the total tablet weight is consistent. Co-processing, ordered mixing, dry granulation, or controlled particle-size distribution can reduce this risk.

What excipients are most valuable for acetaminophen and codeine liquids?

Oral solutions create the largest excipient-driven differentiation opportunity, but they also carry the highest medication-error risk.

A liquid formulation may require:

• Aqueous vehicle such as purified water.
• Co-solvent where justified by solubility and safety.
• Buffer system for pH control.
• Preservative system.
• Sweetener and flavor system.
• Viscosity modifier.
• Chelating agent where compatible with stability.
• Colorant, if necessary for product identification.

The formulation must maintain chemical stability of both active ingredients, preserve against microbial growth, remain palatable, and deliver a reproducible dose from the supplied device. FDA’s Inactive Ingredient Database can support excipient precedent analysis, but the database does not replace formulation-specific safety and compatibility testing.[2]

Which liquid formulation opportunities are commercially attractive?

The strongest opportunities are:

1. Low-volume concentrated liquids with calibrated oral syringes.
2. Alcohol-free and sugar-free formulations.
3. Improved taste masking for adult and adolescent patients.
4. Unit-dose cups or prefilled oral syringes for institutional use.
5. Packaging that reduces dosing confusion between milligrams and milliliters.
6. Preservative systems that support longer in-use stability.

Concentrated products can reduce shipping and storage costs, but they increase overdose risk if concentration differences are not clearly communicated. FDA has repeatedly identified dosing-device design and concentration labeling as important safety controls for liquid medicines.[3]

A commercial product should use a dedicated oral syringe rather than relying on household spoons. The label, carton, bottle, and device should express the dose in the same units and identify the acetaminophen amount prominently.

What patent protection covers acetaminophen and codeine products?

The active ingredients are long-established, and composition-of-matter exclusivity is not available for the basic combination. Patent value, where present, is more likely to arise from:

• Specific liquid formulations.
• Taste-masking systems.
• Controlled-release matrices.
• Abuse-deterrent dosage forms.
• Manufacturing processes.
• Specialized packaging or dosing systems.
• New therapeutic uses, subject to statutory and obviousness limitations.

Legacy immediate-release tablets generally have weak patent barriers. The commercial position is usually determined by FDA approval, manufacturing economics, controlled-substance compliance, supply reliability, and customer contracts rather than by a blocking patent.

What is the Orange Book status of acetaminophen and codeine?

The FDA Orange Book should be reviewed by product-specific NDA, ANDA, strength, and dosage form. A sponsor should not assume that the absence of a patent on a familiar brand name means that every formulation is unprotected. A newly approved liquid, modified-release product, or drug-delivery system may have listed patents even when the active ingredients are old.

For a generic applicant, the relevant diligence includes:

Issue	Required analysis
Listed patents	Identify patents tied to the specific reference product
Exclusivity	Check any remaining New Chemical Entity, pediatric, orphan, or other listed exclusivity
Paragraph IV	Assess whether a certification challenges listed patents
Paragraph III	Determine whether approval is deferred until patent expiration
Label carve-out	Evaluate method-of-use claims that can be omitted
Regulatory exclusivity	Separate FDA exclusivity from patent term
Litigation	Search district-court and Federal Circuit records

For mature acetaminophen-codeine products, the expected risk from active ingredient patents is low. Formulation-specific patents remain the principal exception.

When does acetaminophen and codeine lose exclusivity?

The combination lost meaningful basic-drug exclusivity long ago. The relevant commercial question is not when the combination loses exclusivity, but whether a particular branded formulation has residual listed patents, regulatory exclusivity, or contractual market protection.

A generic launch can occur when:

• The applicable patents have expired or been successfully challenged.
• Any regulatory exclusivity has ended.
• FDA approves the ANDA or 505(b)(2) application.
• The applicant satisfies controlled-substance requirements.
• The product meets bioequivalence, quality, labeling, and manufacturing requirements.

Patent expiry should be assessed at the product level. A formulation patent may expire later than the underlying active-ingredient rights. A pediatric extension can add six months to eligible patent or exclusivity periods, although its applicability depends on the FDA order and product history.[4]

Which formulation patents could create commercial value?

A formulation patent is commercially stronger when it protects a measurable product advantage that is difficult to design around. Potentially valuable claim areas include:

Taste-masked oral liquids

Claims can target a specific flavor system, pH range, sweetener combination, ion-exchange resin, complexing agent, or polymeric coating. The patent is more defensible if it links the excipient system to improved palatability without impairing dissolution or stability.

Low-dose codeine uniformity

A patent may address particle engineering, granulation, ordered mixing, or a defined excipient-to-drug ratio that reduces segregation. The commercial value depends on whether the process produces a meaningful content-uniformity advantage at manufacturing scale.

Abuse-deterrent systems

Physical barriers such as gelling, excessive viscosity, hardening, or resistance to crushing may support a differentiated product. FDA approval for an abuse-deterrent claim requires product-specific evidence and labeling review. Excipients alone do not establish abuse-deterrent status.[5]

Dose-delivery packaging

Unit-dose systems, integrated oral syringes, and tamper-evident packaging can create commercial differentiation. Packaging claims generally provide narrower protection than formulation claims and may be easier to design around.

What FDA regulatory issues affect commercial launch?

Acetaminophen and codeine products face several regulatory constraints.

Opioid scheduling

The applicable schedule depends on dosage form and acetaminophen content. Federal law classifies some codeine combination products differently from higher-codeine products. State requirements may be stricter. Manufacturers must maintain controlled-substance registrations, security procedures, inventory records, and distribution controls under the Controlled Substances Act and DEA regulations.[6]

Pediatric restrictions

FDA has contraindicated codeine use in children younger than 12 years and has restricted use in certain adolescents because of respiratory-depression risk. Codeine is also contraindicated for postoperative pain in patients younger than 18 after tonsillectomy or adenoidectomy.[7]

These restrictions reduce the addressable pediatric market and complicate pediatric liquid positioning. A liquid product should not be marketed with pediatric dosing assumptions that conflict with the approved label.

Acetaminophen toxicity

The formulation and labeling must reduce the risk that patients combine the product with other acetaminophen-containing medicines. FDA has limited prescription combination products to no more than 325 mg acetaminophen per dosage unit in many products and has required label changes to emphasize severe liver injury risk.[1]

Bioequivalence and inactive ingredients

For an ANDA, excipient changes can affect dissolution, absorption, stability, and tolerability. A formulation should be developed around the reference product’s critical quality attributes, not simply around an inexpensive excipient list. The FDA’s product-specific guidance, where available, should control dissolution and bioequivalence planning.[8]

How strong is the patent estate for acetaminophen and codeine?

The patent estate is weak for conventional immediate-release products and potentially moderate for a differentiated delivery system.

Asset type	Expected patent strength	Commercial assessment
Basic acetaminophen-codeine combination	Very low	No meaningful new-molecule protection
Conventional immediate-release tablet	Low	Competition focuses on cost and supply
Taste-masked liquid	Moderate	Value depends on measurable performance
Abuse-deterrent formulation	Moderate to high	Higher development and regulatory burden
Novel delivery device	Moderate	May create procurement differentiation
Manufacturing process	Low to moderate	Stronger if process is hard to replicate
Modified-release product	Moderate	Safety and regulatory risks are substantial

Patent strength depends on claim breadth, prior art, enablement, written description, freedom to operate, and the ease of substituting another excipient or process. A narrow claim covering one sweetener ratio or one polymer grade is unlikely to create durable market power unless the performance benefit is difficult to reproduce.

Which companies are competing in the market?

Competition is fragmented among branded-product owners, generic manufacturers, contract development and manufacturing organizations, and excipient suppliers. Relevant participants can include:

• Generic pharmaceutical companies with approved acetaminophen-codeine ANDAs.
• Branded analgesic companies with legacy or authorized-generic products.
• Controlled-substance manufacturers with DEA-compliant production capacity.
• Excipients suppliers offering direct-compression, taste-masking, coating, and preservation systems.
• Packaging companies supplying calibrated oral syringes and unit-dose systems.

Because the product is mature, manufacturing scale and compliance often matter more than brand equity. A supplier with a reliable codeine API source, validated segregation controls, and established DEA procedures can compete effectively even without a large patent portfolio.

What generic entry risks exist?

Generic entry risk is high for unprotected immediate-release products. The main launch risks are operational rather than patent-driven:

• Codeine API shortages or quota constraints.
• DEA registration and inventory-control failures.
• Cross-contamination during multiproduct manufacturing.
• Content-uniformity failures from low-dose codeine distribution.
• Dissolution differences caused by lubricant or disintegrant selection.
• Liquid microbial contamination.
• Labeling errors involving milligrams, milliliters, or acetaminophen warnings.
• Product recalls from packaging or dosing-device defects.

Paragraph IV litigation is possible where a branded reference product has listed formulation or delivery patents. For legacy immediate-release products with no relevant active listed patents, Paragraph IV exposure is generally limited.

How can excipient strategy create commercial opportunity?

A high-value development program should prioritize one of four positions:

Low-cost generic platform

Use direct compression, a limited excipient set, high-throughput tooling, and a robust dissolution profile. The objective is cost leadership and reliable supply.

Patient-friendly tablet

Reduce tablet size, improve swallowability, add film coating, and differentiate appearance without altering release. This can support retail and institutional procurement.

Safer liquid platform

Combine taste masking, calibrated dosing, alcohol-free formulation, and packaging designed to reduce medication errors. This is the most practical specialty opportunity.

Manufacturing-protected process

Develop a powder-handling or granulation process that produces consistent codeine distribution at scale. Process claims should be supported by comparative data showing improved content uniformity, yield, or stability.

Revenue exposure is greatest in products with recurring institutional demand, high-volume generic contracts, and stable reimbursement. Exact product revenue depends on manufacturer, dosage form, channel, and market, but the mature combination generally offers lower price realization than novel analgesics.

Key Takeaways

• Acetaminophen and codeine is a mature combination with minimal basic patent protection.
• Immediate-release tablets are primarily a manufacturing and supply-chain business.
• Oral liquids offer the strongest excipient-led differentiation but carry greater dosing and safety risks.
• Taste masking, low-dose content uniformity, stability, and calibrated dosing devices are the most valuable development targets.
• Formulation patents can create moderate protection when claims cover measurable performance and are difficult to design around.
• FDA restrictions on pediatric codeine use materially limit pediatric positioning.
• Controlled-substance compliance and acetaminophen toxicity warnings are central launch requirements.
• Generic entry risk is high where no active formulation patents remain.
• The best commercial strategy is a differentiated liquid or a low-cost, high-reliability immediate-release platform.

FAQs

Can acetaminophen and codeine be formulated as an abuse-deterrent product?

Yes, but the product would require formulation-specific abuse-deterrence evidence and FDA review. Conventional excipients in an immediate-release tablet do not support an abuse-deterrent claim by themselves.

Which excipient best improves codeine content uniformity?

No single excipient is universally superior. Content uniformity usually depends on particle-size control, ordered mixing, granulation, powder flow, and segregation resistance. Microcrystalline cellulose and co-processed direct-compression systems are common starting points, subject to development data.

Is an alcohol-free acetaminophen-codeine liquid commercially valuable?

Yes. Alcohol-free formulation, improved taste, calibrated dosing, and unit-dose packaging can differentiate a mature product, particularly in institutional and adult-care settings. The label and dosing device must address opioid and acetaminophen risks.

Can a new excipient combination obtain patent protection?

Yes, if the combination is novel, nonobvious, enabled, and tied to a credible technical effect. A narrow excipient ratio without demonstrated performance may have limited patent strength.

Does codeine scheduling affect excipient and packaging strategy?

Yes. Scheduling affects manufacturing security, inventory records, distribution controls, facility registration, and product handling. Packaging that improves reconciliation and reduces dosing errors can have commercial value beyond the formulation itself.

References

1. U.S. Food and Drug Administration. (2011). FDA limits prescription combination drug products that contain more than 325 mg of acetaminophen. https://www.fda.gov
2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveIngredient
3. U.S. Food and Drug Administration. (2011). Questions and answers on FDA’s withdrawal of prescription oral transmucosal fentanyl citrate products. https://www.fda.gov
4. U.S. Food and Drug Administration. (n.d.). Generic drug user fee amendments and regulatory exclusivity. https://www.fda.gov
5. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov
6. Drug Enforcement Administration. (n.d.). Controlled substances act. https://www.dea.gov
7. U.S. Food and Drug Administration. (2017). FDA drug safety communication: FDA evaluates risks of using codeine cough-and-cold medicines in children. https://www.fda.gov
8. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. https://www.fda.gov